Management ChangeMay 15, 2026, 04:27 PM
Anavex Life Sciences COO Felix Lauscher Departs
AI Summary
Anavex Life Sciences Corp. announced the departure of Felix Lauscher from his role as Chief Operating Officer on May 11, 2026. His departure is part of a broader reorganization of duties following the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer. During his tenure, Mr. Lauscher received a prorated annual base salary of $264,000 and was granted 50,000 stock options, of which 4,167 vested and remain exercisable. He was also offered two weeks' compensation in exchange for a general release.
Key Highlights
- Felix Lauscher departed as Chief Operating Officer of Anavex Life Sciences Corp. on May 11, 2026.
- His departure is part of a broader reorganization following the appointment of Dr. Terrie Kellmeyer as Interim CEO.
- Mr. Lauscher served as COO since March 1, 2026.
- His annual base salary was $264,000.
- He was granted 50,000 stock options, with 45,833 forfeited upon departure.
- 4,167 options vested on March 31, 2026, exercisable until August 9, 2026, at $4.69 per share.
- He was offered two weeks' additional compensation for executing a general release.
Price Impact
More from AVXL